Search

Your search keyword '"Mellemgaard, Anders"' showing total 427 results
Start Over Author "Mellemgaard, Anders"
427 results on '"Mellemgaard, Anders"'

3. Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark

Author

Hedgeman, Elizabeth, Nørgaard, Mette, Dalvi, Tapashi, Pedersen, Lars, Hansen, Hanh Pham, Walker, Jill, Midha, Anita, Shire, Norah, Boothman, Anne-Marie, Fryzek, Jon P., Rigas, James, Mellemgaard, Anders, Rasmussen, Torben R., Hamilton-Dutoit, Stephen, and Cronin-Fenton, Deirdre

Published
2021
Full Text
View/download PDF

6. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Author

Yang, Jin-Ji, Fang, Jian, Shu, Yong-Qian, Chang, Jian-Hua, Chen, Gong-Yan, He, Jian Xing, Li, Wei, Liu, Xiao-Qing, Yang, Nong, Zhou, Caicun, Huang, Jian An, Frigault, Melanie M., Hartmaier, Ryan, Ahmed, Ghada F., Egile, Coumaran, Morgan, Shethah, Verheijen, Remy B., Mellemgaard, Anders, Yang, Liu, and Wu, Yi-Long

Published
2021
Full Text
View/download PDF

8. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Author

Sequist, Lecia V, Han, Ji-Youn, Ahn, Myung-Ju, Cho, Byoung Chul, Yu, Helena, Kim, Sang-We, Yang, James Chih-Hsin, Lee, Jong Seok, Su, Wu-Chou, Kowalski, Dariusz, Orlov, Sergey, Cantarini, Mireille, Verheijen, Remy B, Mellemgaard, Anders, Ottesen, Lone, Frewer, Paul, Ou, Xiaoling, and Oxnard, Geoffrey

Published
2020
Full Text
View/download PDF

9. Detection and characterization of lung cancer using cell-free DNA fragmentomes

Author

Mathios, Dimitrios, Johansen, Jakob Sidenius, Cristiano, Stephen, Medina, Jamie E., Phallen, Jillian, Larsen, Klaus R., Bruhm, Daniel C., Niknafs, Noushin, Ferreira, Leonardo, Adleff, Vilmos, Chiao, Jia Yuee, Leal, Alessandro, Noe, Michael, White, James R., Arun, Adith S., Hruban, Carolyn, Annapragada, Akshaya V., Jensen, Sarah Østrup, Ørntoft, Mai-Britt Worm, Madsen, Anders Husted, Carvalho, Beatriz, de Wit, Meike, Carey, Jacob, Dracopoli, Nicholas C., Maddala, Tara, Fang, Kenneth C., Hartman, Anne-Renee, Forde, Patrick M., Anagnostou, Valsamo, Brahmer, Julie R., Fijneman, Remond J. A., Nielsen, Hans Jørgen, Meijer, Gerrit A., Andersen, Claus Lindbjerg, Mellemgaard, Anders, Bojesen, Stig E., Scharpf, Robert B., and Velculescu, Victor E.

Published
2021
Full Text
View/download PDF

12. Protein-altering germline mutations implicate novel genes related to lung cancer development

Author

Ji, Xuemei, Mukherjee, Semanti, Landi, Maria Teresa, Bosse, Yohan, Joubert, Philippe, Zhu, Dakai, Gorlov, Ivan, Xiao, Xiangjun, Han, Younghun, Gorlova, Olga, Hung, Rayjean J., Brhane, Yonathan, Carreras-Torres, Robert, Christiani, David C., Caporaso, Neil, Johansson, Mattias, Liu, Geoffrey, Bojesen, Stig E., Le Marchand, Loic, Albanes, Demetrios, Bickeböller, Heike, Aldrich, Melinda C., Bush, William S., Tardon, Adonina, Rennert, Gad, Chen, Chu, Byun, Jinyoung, Dragnev, Konstantin H., Field, John K., Kiemeney, Lambertus FA., Lazarus, Philip, Zienolddiny, Shan, Lam, Stephen, Schabath, Matthew B., Andrew, Angeline S., Bertazzi, Pier A., Pesatori, Angela C., Diao, Nancy, Su, Li, Song, Lei, Zhang, Ruyang, Leighl, Natasha, Johansen, Jakob S., Mellemgaard, Anders, Saliba, Walid, Haiman, Christopher, Wilkens, Lynne, Fernandez-Somoano, Ana, Fernandez-Tardon, Guillermo, Heijden, Erik H. F. M. van der, Kim, Jin Hee, Davies, Michael P. A., Marcus, Michael W., Brunnström, Hans, Manjer, Jonas, Melander, Olle, Muller, David C., Overvad, Kim, Trichopoulou, Antonia, Tumino, Rosario, Goodman, Gary E., Cox, Angela, Taylor, Fiona, Woll, Penella, Wichmann, Erich, Muley, Thomas, Risch, Angela, Rosenberger, Albert, Grankvist, Kjell, Johansson, Mikael, Shepherd, Frances, Tsao, Ming-Sound, Arnold, Susanne M., Haura, Eric B., Bolca, Ciprian, Holcatova, Ivana, Janout, Vladimir, Kontic, Milica, Lissowska, Jolanta, Mukeria, Anush, Ognjanovic, Simona, Orlowski, Tadeusz M., Scelo, Ghislaine, Swiatkowska, Beata, Zaridze, David, Bakke, Per, Skaug, Vidar, Butler, Lesley M., Offit, Kenneth, Srinivasan, Preethi, Bandlamudi, Chaitanya, Hellmann, Matthew D., Solit, David B., Robson, Mark E., Rudin, Charles M., Stadler, Zsofia K., Taylor, Barry S., Berger, Michael F., Houlston, Richard, McLaughlin, John, Stevens, Victoria, Nickle, David C., Obeidat, Ma’en, Timens, Wim, Artigas, María Soler, Shete, Sanjay, Brenner, Hermann, Chanock, Stephen, Brennan, Paul, McKay, James D., and Amos, Christopher I.

Published
2020
Full Text
View/download PDF

13. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Author

Scagliotti, Giorgio Vittorio, primary, Parikh, Purvish, additional, von Pawel, Joachim, additional, Biesma, Bonne, additional, Vansteenkiste, Johan, additional, Manegold, Christian, additional, Serwatowski, Piotr, additional, Gatzemeier, Ulrich, additional, Digumarti, Raghunadharao, additional, Zukin, Mauro, additional, Lee, Jin S., additional, Mellemgaard, Anders, additional, Park, Keunchil, additional, Patil, Shehkar, additional, Rolski, Janusz, additional, Goksel, Tuncay, additional, de Marinis, Filippo, additional, Simms, Lorinda, additional, Sugarman, Katherine P., additional, and Gandara, David, additional

Published
2023
Full Text
View/download PDF

14. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark

Author

Dalvi, Tapashi, primary, Nørgaard, Mette, additional, Fryzek, Jon P., additional, Movva, Naimisha, additional, Pedersen, Lars, additional, Pham Hansen, Hanh, additional, Walker, Jill, additional, Midha, Anita, additional, Shire, Norah, additional, Boothman, Anne-Marie, additional, Rigas, James, additional, Mellemgaard, Anders, additional, Rasmussen, Torben R., additional, Hamilton-Dutoit, Stephen, additional, and Cronin-Fenton, Deirdre, additional

Published
2023
Full Text
View/download PDF

16. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

Author

Iversen, Trine Zeeberg, primary, Engell-Noerregaard, Lotte, primary, Ellebaek, Eva, primary, Andersen, Rikke, primary, Larsen, Stine Kiaer, primary, Bjoern, Jon, primary, Zeyher, Claus, primary, Gouttefangeas, Cécile, primary, Thomsen, Birthe Moerk, primary, Holm, Bente, primary, thor Straten, Per, primary, Mellemgaard, Anders, primary, Andersen, Mads Hald, primary, and Svane, Inge Marie, primary

Published
2023
Full Text
View/download PDF

20. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Author

Novello, Silvia, Kaiser, Rolf, Mellemgaard, Anders, Douillard, Jean-Yves, Orlov, Sergey, Krzakowski, Maciej, von Pawel, Joachim, Gottfried, Maya, Bondarenko, Igor, Liao, Meilin, Barrueco, José, Gaschler-Markefski, Birgit, Griebsch, Ingolf, Palmer, Michael, and Reck, Martin

Published
2015
Full Text
View/download PDF

23. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Author

Reck, Martin, Kaiser, Rolf, Mellemgaard, Anders, Douillard, Jean-Yves, Orlov, Sergey, Krzakowski, Maciej, von Pawel, Joachim, Gottfried, Maya, Bondarenko, Igor, Liao, Meilin, Gann, Claudia-Nanette, Barrueco, José, Gaschler-Markefski, Birgit, and Novello, Silvia

Published
2014
Full Text
View/download PDF

26. An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Author

Scagliotti, Giorgio V., Felip, Enriqueta, Besse, Benjamin, von Pawel, Joachim, Mellemgaard, Anders, Reck, Martin, Bosquee, Lionel, Chouaid, Christos, Lianes-Barragán, Pilar, Paul, Elaine M., Ruiz-Soto, Rodrigo, Sigal, Entisar, Ottesen, Lone H., and LeChevalier, Thierry

Published
2013
Full Text
View/download PDF

27. Association between Health-Related Quality of Life and Completion of First-Line Treatment among Lung Cancer Patients

Author

Levinsen, Anne Katrine G., Dalton, Susanne O., Andersen, Ingelise, Mellemgaard, Anders, Oksen, Marianne S., Saltbaek, Lena, Hansen, Nina H. G., Carlsen, Signe, Kjaer, Trille K., Levinsen, Anne Katrine G., Dalton, Susanne O., Andersen, Ingelise, Mellemgaard, Anders, Oksen, Marianne S., Saltbaek, Lena, Hansen, Nina H. G., Carlsen, Signe, and Kjaer, Trille K.

Abstract

Simple Summary The aim of this study was to investigate how health-related quality of life at time of diagnosis is associated with the completion of planned first-line oncological treatment among lung cancer patients. Patients with reduced function and patients who reported fatigue, pain, appetite loss, and financial difficulties at time of diagnosis had significantly increased adjusted odds ratios for not completing the planned first-line oncological treatment. Measures of lung cancer patients' self-reported HRQOL as part of the diagnostic evaluation at time of diagnosis may contribute to the optimization of planned oncological treatment. Experts recommend assessing lung cancer patients' health-related quality of life (HRQOL) in the diagnostic evaluation. We investigated the association between HRQOL and completion of first-line treatment among lung cancer patients in a prospective cohort study. Clinical information on lung cancer patients was obtained from medical records, and information on quality of life and lung cancer-related symptoms was obtained through questionnaires at time of diagnosis. We used directed acyclic graphs to identify potential confounders and mediators between HRQOL and completion of first-line treatment. The association between functioning levels and symptoms and completion of first-line oncological treatment was estimated as odds ratios, with 95% confidence intervals, in logistic regression models. In all, 137 patients (52% men, mean age: 69 years) participated, out of 216 invited. Patients who reported reduced functioning had significantly increased ORs for not completing first-line treatment: poor physical function (OR 4.44), role function (OR 6.09), emotional function (OR 5.86), and social function (OR 3.13). Patients with fatigue (OR 7.55), pain (OR 6.07), appetite loss (OR 4.66), and financial difficulties (OR 17.23) had significantly increased ORs for not completing the first-line treatment. Reduced functioning and presence of sym

Published
2022

28. The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients

Author

Iachina, Maria, Jakobsen, Erik, Møller, Henrik, Lüchtenborg, Margreet, Mellemgaard, Anders, Krasnik, Mark, and Green, Anders

Subjects
Chronic obstructive lung disease -- Research -- Risk factors, Non-small cell lung cancer -- Research -- Risk factors -- Development and progression -- Care and treatment -- Patient outcomes, Health
Abstract

Purpose Primary lung cancer is one of the most common types of cancers. Comorbidity has been shown to be a negative prognostic factor in the overall lung cancer population. The significance of the individual comorbidities is less well known. The purpose of this paper is to investigate the effect of each comorbid disease groups on survival. Methods The analysis is based on all patients with NSCLC who were registered in 2009-2011, in total 10,378 patients. To estimate the effect of each comorbidity group on the survival, we fitted a Cox regression model for each comorbidity group adjusting for age, sex, resection, and stage. Results Patients with cardiovascular comorbidity have a 30 % higher death rate [HR 1.30 with 95 % CI (1.13; 1.49)] than patients without comorbidity. Patients with diabetes and patients with cerebrovascular disorders and COPD have a 20 % excess mortality than patients without comorbidity: [HR 1.19 with CI (1.02; 1.39) for diabetes, HR 1.18 with CI (1.05; 1.33) for cerebrovascular disorders, and HR 1.20 with CI (1.10; 1.39 for COPD)]. Conclusion Our study shows the importance of cardiovascular disease in lung cancer. Diabetes, cerebrovascular disorders, and COPD also have a significant impact on survival of NSCLC patients., Author(s): Maria Iachina[sup.1] [sup.2] , Erik Jakobsen[sup.3] [sup.4] , Henrik Møller[sup.5] , Margreet Lüchtenborg[sup.5] , Anders Mellemgaard[sup.6] , Mark Krasnik[sup.7] , Anders Green[sup.4] Author Affiliations: (1) Center for Clinical Epidemiology, [...]

Published
2015
Full Text
View/download PDF

30. Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials

Author

Eide, Inger Johanne Zwicky, primary, Stensgaard, Simone, additional, Helland, Åslaug, additional, Ekman, Simon, additional, Mellemgaard, Anders, additional, Hansen, Karin Holmskov, additional, Cicenas, Saulius, additional, Koivunen, Jussi, additional, Grønberg, Bjørn Henning, additional, Sørensen, Boe Sandahl, additional, and Brustugun, Odd Terje, additional

Published
2022
Full Text
View/download PDF

38. Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study

Author

Eide, Inger Johanne Zwicky, primary, Grut, Harald, additional, Helland, Åslaug, additional, Ekman, Simon, additional, Sørensen, Jens Benn, additional, Hansen, Karin Holmskov, additional, Grønberg, Bjørn Henning, additional, Cicenas, Saulius, additional, Koivunen, Jussi Pekka, additional, Mellemgaard, Anders, additional, and Brustugun, Odd Terje, additional

Published
2021
Full Text
View/download PDF

39. Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients:results from a phase II study

Author

Eide, Inger Johanne Zwicky, Grut, Harald, Helland, Åslaug, Ekman, Simon, Sørensen, Jens Benn, Hansen, Karin Holmskov, Grønberg, Bjørn Henning, Cicenas, Saulius, Koivunen, Jussi Pekka, Mellemgaard, Anders, Brustugun, Odd Terje, Eide, Inger Johanne Zwicky, Grut, Harald, Helland, Åslaug, Ekman, Simon, Sørensen, Jens Benn, Hansen, Karin Holmskov, Grønberg, Bjørn Henning, Cicenas, Saulius, Koivunen, Jussi Pekka, Mellemgaard, Anders, and Brustugun, Odd Terje

Abstract

Introduction: Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect of osimertinib on brain metastases in both T790M-positive and -negative patients. Methods: The TREM-study was an investigator-initiated phase II, single-arm, multi-institutional clinical trial conducted in Northern Europe. Patients with resistance to prior EGFR-TKIs received osimertinib until radiological progression, unacceptable toxicity or death. Baseline brain scans were performed in patients with known or suspected brain metastases and repeated every 8–12 weeks. We assessed intracranial efficacy in patients with baseline brain metastases. Results: Brain metastases were detected in 48/199 patients at baseline. Of these, 63% were T790M-positive, 27% -negative and 10% had unknown T790M-status. The majority (73%) of the patients had received prior whole brain radiotherapy and additionally 8% had received stereotactic radiosurgery (SRS). Brain scans were available for review for 42 patients. The intracranial progression free survival was 39.7 versus 3.5 months for T790M + and T790M- patients, respectively (p < 0.001). The overall intracranial disease control rate (iDCR) was 81%, and for T790M + and T790M- patients the DCR was 89% versus 55%, respectively. The estimated risk of CNS progression was 0.8% at 6 months and 6% at 12 months for T790M-positive patients, and 14% and 17% at 6 and 12 months, respectively, for the T790M-negative. Conclusion: This subgroup analysis confirms CNS efficacy of osimertinib in patients with the T790M resistance mutation, while other treatment options should be considered for EGFR-TKI relapsed T790M-negative patients with brain metastases.

Published
2021

42. Optimizing COPD treatment in patients with lung- or head and neck cancer does not improve quality of life – a randomized, pilot, clinical trial

Author

Gottlieb, Magnus, Mellemgaard, Anders, Marsaa, Kristoffer, Godtfredsen, Nina, Gottlieb, Magnus, Mellemgaard, Anders, Marsaa, Kristoffer, and Godtfredsen, Nina

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a common comorbidity in patients with lung and head- and neck cancer. Patients with lung cancer who also suffer from COPD have a worse prognosis than patients with lung cancer and no COPD. It has previously been shown that diagnosis and treatment of concomitant COPD in patients with newly diagnosed lung- or head and neck cancer need optimization. In this randomized, controlled trial we aimed to assess if intervention directed at improving treatment for COPD in these patients improved health-related quality of life (QoL). Methods: During 2014, we randomized 114 patients referred for oncological treatment at a large university hospital in the Capital Region of Denmark, to either usual care or intervention regarding concomitant COPD. The intervention consisted of two visits in an out-patient clinic established at the oncological department and staffed with a pulmonary physician. At baseline, week 13 and week 25, all patients filled out the cancer- and COPD-specific QoL questionnaires CAT and EORTC, respectively. The primary outcome was change in CAT-score between control- and intervention group. The secondary outcome was change in EORTC. Results: There was no change in CAT-score by week 13 or 25 between the groups. For the EORTC there was a statistically significant improvement only in the fatigue domain at week 13 (p = 0.03), but not at week 25. There was a trend towards less dyspnea in the intervention group at week 13, measured by EORTC (p = 0.07). Mortality by week 25 was similar in both groups. Conclusion: In this population of severely ill cancer patients, we did not find that this intervention, focusing on inhaled COPD medication, for the management of COPD had any convincing positive impact on the patients’ perceived quality of life compared with usual care. Further studies are needed.

Published
2020

43. A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval

Author

Sahota, Tarjinder, primary, Dota, Corina D., additional, Vik, Torbjörn, additional, Yan, Weili, additional, Verheijen, Remy B., additional, Walker, Stephen, additional, Li, Yan, additional, Goldwater, Ronald, additional, Ghiorghiu, Dana, additional, Mellemgaard, Anders, additional, and Ahmed, Ghada F., additional

Published
2021
Full Text
View/download PDF

44. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Author

Yang, Jin-Ji, primary, Fang, Jian, additional, Shu, Yong-Qian, additional, Chang, Jian-Hua, additional, Chen, Gong-Yan, additional, He, Jian Xing, additional, Li, Wei, additional, Liu, Xiao-Qing, additional, Yang, Nong, additional, Zhou, Caicun, additional, Huang, Jian An, additional, Frigault, Melanie M., additional, Hartmaier, Ryan, additional, Ahmed, Ghada F., additional, Egile, Coumaran, additional, Morgan, Shethah, additional, Verheijen, Remy B., additional, Mellemgaard, Anders, additional, Yang, Liu, additional, and Wu, Yi-Long, additional

Published
2020
Full Text
View/download PDF

45. Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma

Author

Choueiri, Toni K., primary, Heng, Daniel Y. C., additional, Lee, Jae Lyun, additional, Cancel, Mathilde, additional, Verheijen, Remy B., additional, Mellemgaard, Anders, additional, Ottesen, Lone H., additional, Frigault, Melanie M., additional, L’Hernault, Anne, additional, Szijgyarto, Zsolt, additional, Signoretti, Sabina, additional, and Albiges, Laurence, additional

Published
2020
Full Text
View/download PDF

46. MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.

Author

Albiges, Laurence, primary, Heng, Daniel Yick Chin, additional, Lee, Jae-Lyun, additional, Walker, Stephen, additional, Mellemgaard, Anders, additional, Ottesen, Lone, additional, Frigault, Melanie M., additional, L'Hernault, Anne, additional, Wessen, Jonathan, additional, Choueiri, Toni K., additional, Cancel, Mathilde, additional, and Signoretti, Sabina, additional

Published
2020
Full Text
View/download PDF

47. SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).

Author

Choueiri, Toni K., primary, Heng, Daniel Yick Chin, additional, Lee, Jae-Lyun, additional, Cancel, Mathilde, additional, Verheijen, Remy B, additional, Mellemgaard, Anders, additional, Ottesen, Lone, additional, Frigault, Melanie M., additional, L'Hernault, Anne, additional, Szijgyarto, Zsolt, additional, Signoretti, Sabina, additional, and Albiges, Laurence, additional

Published
2020
Full Text
View/download PDF

48. A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Author

Yang, Jin-Ji, primary, Fang, Jian, additional, Shu, Yong-Qian, additional, Chang, Jian-Hua, additional, Chen, Gong-Yan, additional, He, Jian Xing, additional, Li, Wei, additional, Liu, Xiao-Qing, additional, Yang, Nong, additional, Zhou, Caicun, additional, Huang, Jian An, additional, Frigault, Melanie M., additional, Hartmaier, Ryan, additional, Ahmed, Ghada F., additional, Egile, Coumaran, additional, Morgan, Shethah, additional, Verheijen, Remy B., additional, Mellemgaard, Anders, additional, Yang, Liu, additional, and Wu, Yi-Long, additional

Published
2020
Full Text
View/download PDF

50. Lungesygdomme

Author

Backer, Vibeke, Mortensen, Jann, Hostrup, Morten, Hansen, Hanne, Godtfredsen, Nina Skavlan, Shaker, Saher, Ulrik, Charlotte Suppli, Seersholm, Niels, Titlestad, Ingrid Louise, Hilberg, Ole, Konge, Lars, Clementsen, Paul Frost, Mellemgaard, Anders, Rasmussen, Torben Riis, Tønnesen, Philip, Hansen, Ejvind Frausing, Bülow, Hans-Henrik, Perch, Michael, Lund, Thomas Kromann, Vestbo, Jørgen, Lange, Peter, Fausbøll Mosbech, Holger, Bendstrup, Elisabeth, Jennum, Poul, Armbruster, Karin, Ringbæk, Thomas, Bødtger, Uffe, Ravn, Jesper, Sørensen, Jens Benn, de Muckadell, Ove B. Schaffalitzky, Hastrup Svendsen, Jesper, and Vilstrup, Hendrik

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results